Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures: a systematic review and metaanalysis

Faulkner, Harrison; Chakankar, Shubham; Mammi, Marco; Lo, Jack Yu Tung; Doucette, Joanne; Alotaibi, Nawaf M.; Abboud, Judi; Le, Andrew; Mekary, Rania A.; Bunevičius, Adomas

doi:10.1007/s10143-020-01406-z

Cited by 6 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because thrombin and factor Xa are central to the hemostatic response to injury, these drugs increase a patient's risk for severe bleeding, including life‐threatening intracranial and gastrointestinal hemorrhage 1–4 . This reality has led to development of strategies for preventing or stopping anticoagulant‐associated bleeding based on neutralizing or bypassing the anticoagulant 2,5,6 or, in the case of vitamin K antagonists, reconstituting normal levels of coagulation factors 7,8 …”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4] This reality has led to development of strategies for preventing or stopping anticoagulant-associated bleeding based on neutralizing or bypassing the anticoagulant 2,5,6 or, in the case of vitamin K antagonists, reconstituting normal levels of coagulation factors. 7,8 There has been substantial interest over the past 2 decades in identifying targets for antithrombotic drugs that play a smaller role in hemostasis than do thrombin and factor Xa. Inhibition of such targets is expected to produce safer anticoagulation from the standpoint of therapy-induced bleeding.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors

Salomon

Gailani

2022

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Several drugs that reduce functional levels of the plasma protease zymogen factor XI (FXI), or that inhibit its activated form (FXIa), are being evaluated as treatments to prevent thrombosis. Based on the observation that individuals with inherited FXI deficiency have a relatively mild bleeding disorder, it is anticipated that therapeutic FXI(a) inhibitors will have a smaller impact on hemostasis than anticoagulants targeting thrombin or factor Xa. However, even if FXI(a) inhibitors are determined to be safer than currently used anticoagulants, some patients on these drugs will experience abnormal bleeding or require emergent surgery. Strategies for dealing with such situations are required. Treatment with antifibrinolytic agents and low doses of recombinant factor VIIa effectively prevent abnormal bleeding in FXI‐deficient patients with alloantibody inhibitors to FXI who undergo surgery. We propose that a similar strategy can be used for patients on therapeutic FXI(a) inhibitors who are bleeding or require invasive procedures.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors

Salomon

Gailani

2022

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Das thromboembolische-Risiko nach Gabe von PPSB wird mit ca. 5–6 % angegeben [ 68 ]. Bei einer bekannten Heparin-induzierten Thrombozytopenie darf nur heparinfreies PPSB verabreicht werden.…”

Section: Antagonisierung Von Antikoagulanzien Und Plättchenhemmernunclassified

Update on point-of-care-based coagulation treatment

Schmitt,

Schöchl,

Brün

et al. 2024

Anaesthesiologie

View full text Add to dashboard Cite

ZusammenfassungPoint-of-care(POC)-taugliche viskoelastische Testverfahren (VET) sind im klinischen Einsatz weitverbreitet. Aufgrund des erweiterten Spektrums an verfügbaren Geräten und insbesondere durch die Entwicklung neuer Testansätze bzw. -methoden ist aus Sicht der Autoren ein Update der aktuellen Behandlungsalgorithmen notwendig. Ziel dieses Artikels ist es, einen Überblick sowohl über die aktuell verfügbaren VET-Geräte als auch über die dazugehörigen Reagenzien zu vermitteln. Darüber hinaus werden 2 Therapiealgorithmen für die am häufigsten im deutschsprachigen Raum eingesetzten VET-Geräte vorgestellt.

show abstract

Hämostase

Miesbach¹,

Schöchl²

2023

Die Intensivmedizin

View full text Add to dashboard Cite

Safety and efficacy of prothrombin complex concentrate (PCC) for anticoagulation reversal in patients undergoing urgent neurosurgical procedures: a systematic review and metaanalysis

Cited by 6 publications

References 57 publications

A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors

A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors

Update on point-of-care-based coagulation treatment

Hämostase

Contact Info

Product

Resources

About